| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Justin Fischedick, Frank Van Der Kooy, Robert Verpoort. Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor. Chemical & pharmaceutical bulletin. vol 58. issue 2. 2010-04-22. PMID:20118579. |
the top five major compounds in bedrocan extracts were delta(9)-thc, cannabigerol (cbg), terpinolene, myrcene, and cis-ocimene in bedrobinol delta(9)-thc, myrcene, cbg, cannabichromene (cbc), and camphene in bediol cannabidiol (cbd), delta(9)-thc, myrcene, cbc, and cbg. |
2010-04-22 |
2023-08-12 |
Not clear |
| Justin Fischedick, Frank Van Der Kooy, Robert Verpoort. Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor. Chemical & pharmaceutical bulletin. vol 58. issue 2. 2010-04-22. PMID:20118579. |
there was no statistically significant difference between cb1 binding of pure delta(9)-thc compared to cannabis smoke and vapor at an equivalent concentration of delta(9)-thc. |
2010-04-22 |
2023-08-12 |
Not clear |
| Frances R Levin, John J Mariani, Daniel J Brooks, Shan Xie, Kathleen A Murra. Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol. Drug and alcohol dependence. vol 106. issue 1. 2010-04-09. PMID:19733018. |
the purpose of this study was to determine whether delta(9)-tetrahydrocannabivarin (thcv), a plant cannabinoid, is a sensitive measure to detect recent marijuana use in cannabis dependent patients. |
2010-04-09 |
2023-08-12 |
Not clear |
| Diego Centonze, Francesco Mori, Giacomo Koch, Fabio Buttari, Claudia Codecà, Silvia Rossi, Maria Teresa Cencioni, Monica Bari, Stefania Fiore, Giorgio Bernardi, Luca Battistini, Mauro Maccarron. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. vol 30. issue 6. 2010-03-22. PMID:19768368. |
a cannabis-based medication containing delta(9)-tetrahydrocannabinol and cannabidiol (sativex) has been approved in some countries for the treatment of ms-associated pain. |
2010-03-22 |
2023-08-12 |
Not clear |
| Jahan P Marcu, Rigel T Christian, Darryl Lau, Anne J Zielinski, Maxx P Horowitz, Jasmine Lee, Arash Pakdel, Juanita Allison, Chandani Limbad, Dan H Moore, Garret L Yount, Pierre-Yves Desprez, Sean D McAlliste. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Molecular cancer therapeutics. vol 9. issue 1. 2010-03-22. PMID:20053780. |
we therefore tested cannabidiol, the second most abundant plant-derived cannabinoid, in combination with delta(9)-thc. |
2010-03-22 |
2023-08-12 |
human |
| Jahan P Marcu, Rigel T Christian, Darryl Lau, Anne J Zielinski, Maxx P Horowitz, Jasmine Lee, Arash Pakdel, Juanita Allison, Chandani Limbad, Dan H Moore, Garret L Yount, Pierre-Yves Desprez, Sean D McAlliste. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Molecular cancer therapeutics. vol 9. issue 1. 2010-03-22. PMID:20053780. |
in the u251 and sf126 glioblastoma cell lines, delta(9)-thc and cannabidiol acted synergistically to inhibit cell proliferation. |
2010-03-22 |
2023-08-12 |
human |
| Jahan P Marcu, Rigel T Christian, Darryl Lau, Anne J Zielinski, Maxx P Horowitz, Jasmine Lee, Arash Pakdel, Juanita Allison, Chandani Limbad, Dan H Moore, Garret L Yount, Pierre-Yves Desprez, Sean D McAlliste. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Molecular cancer therapeutics. vol 9. issue 1. 2010-03-22. PMID:20053780. |
our results suggest that the addition of cannabidiol to delta(9)-thc may improve the overall effectiveness of delta(9)-thc in the treatment of glioblastoma in cancer patients. |
2010-03-22 |
2023-08-12 |
human |
| Erin L Karschner, Eugene W Schwilke, Ross H Lowe, W David Darwin, Harrison G Pope, Ronald Herning, Jean L Cadet, Marilyn A Huesti. Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction (Abingdon, England). vol 104. issue 12. 2010-03-17. PMID:19804462. |
to quantify blood delta(9)-tetrahydrocannabinol (thc) concentrations in chronic cannabis users over 7 days of continuous monitored abstinence. |
2010-03-17 |
2023-08-12 |
Not clear |
| Marta Di Forti, Craig Morgan, Paola Dazzan, Carmine Pariante, Valeria Mondelli, Tiago Reis Marques, Rowena Handley, Sonija Luzi, Manuela Russo, Alessandra Paparelli, Alexander Butt, Simona A Stilo, Ben Wiffen, John Powell, Robin M Murra. High-potency cannabis and the risk of psychosis. The British journal of psychiatry : the journal of mental science. vol 195. issue 6. 2010-03-10. PMID:19949195. |
people who use cannabis have an increased risk of psychosis, an effect attributed to the active ingredient delta 9-tetrahydrocannabinol (delta 9-thc). |
2010-03-10 |
2023-08-12 |
Not clear |
| Marta Di Forti, Craig Morgan, Paola Dazzan, Carmine Pariante, Valeria Mondelli, Tiago Reis Marques, Rowena Handley, Sonija Luzi, Manuela Russo, Alessandra Paparelli, Alexander Butt, Simona A Stilo, Ben Wiffen, John Powell, Robin M Murra. High-potency cannabis and the risk of psychosis. The British journal of psychiatry : the journal of mental science. vol 195. issue 6. 2010-03-10. PMID:19949195. |
there has recently been concern over an increase in the concentration of delta 9-thc in the cannabis available in many countries. |
2010-03-10 |
2023-08-12 |
Not clear |
| Itai Bab, Andreas Zimmer, Eitan Melame. Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Annals of medicine. vol 41. issue 8. 2010-03-09. PMID:19634029. |
the active component of marijuana, delta(9)-tetrahydrocannabinol, activates the cb1 and cb2 cannabinoid receptors, thus mimicking the action of endogenous cannabinoids. |
2010-03-09 |
2023-08-12 |
mouse |
| Gilberto Gerra, Amir Zaimovic, Maria L Gerra, Roberto Ciccocioppo, Andrea Cippitelli, Giovanni Serpelloni, Lorenzo Somain. Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists. Recent patents on CNS drug discovery. vol 5. issue 1. 2010-03-01. PMID:19832688. |
delta(9)-tetrahydrocannabinol (thc) is the main active ingredient of cannabis. |
2010-03-01 |
2023-08-12 |
Not clear |
| Jonathan Z Long, Daniel K Nomura, Robert E Vann, D Matthew Walentiny, Lamont Booker, Xin Jin, James J Burston, Laura J Sim-Selley, Aron H Lichtman, Jenny L Wiley, Benjamin F Cravat. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proceedings of the National Academy of Sciences of the United States of America. vol 106. issue 48. 2010-02-18. PMID:19918051. |
delta(9)-tetrahydrocannabinol (thc), the psychoactive component of marijuana, and other direct cannabinoid receptor (cb1) agonists produce a number of neurobehavioral effects in mammals that range from the beneficial (analgesia) to the untoward (abuse potential). |
2010-02-18 |
2023-08-12 |
Not clear |
| N Gunasekaran, L E Long, B L Dawson, G H Hansen, D P Richardson, K M Li, J C Arnold, I S McGrego. Reintoxication: the release of fat-stored delta(9)-tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure. British journal of pharmacology. vol 158. issue 5. 2010-02-12. PMID:19681888. |
delta(9)-tetrahydrocannabinol (thc), the main psychoactive constituent of cannabis, accumulates in adipose tissue where it is stored for long periods of time. |
2010-02-12 |
2023-08-12 |
Not clear |
| Josée Guindon, Andrea G Hohman. The endocannabinoid system and pain. CNS & neurological disorders drug targets. vol 8. issue 6. 2010-02-12. PMID:19839937. |
endocannabinoids, the brain's own cannabis-like substances, share the same molecular target as delta(9)-tetrahydrocannabinol, the main psychoactive component in cannabis. |
2010-02-12 |
2023-08-12 |
Not clear |
| Ewa Kozela, Maciej Pietr, Ana Juknat, Neta Rimmerman, Rivka Levy, Zvi Voge. Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. The Journal of biological chemistry. vol 285. issue 3. 2010-02-08. PMID:19910459. |
cannabinoids delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated nf-kappab and interferon-beta/stat proinflammatory pathways in bv-2 microglial cells. |
2010-02-08 |
2023-08-12 |
mouse |
| Ewa Kozela, Maciej Pietr, Ana Juknat, Neta Rimmerman, Rivka Levy, Zvi Voge. Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. The Journal of biological chemistry. vol 285. issue 3. 2010-02-08. PMID:19910459. |
we found that the two major cannabinoids present in marijuana, delta(9)-tetrahydrocannabinol (thc) and cannabidiol (cbd), decrease the production and release of proinflammatory cytokines, including interleukin-1beta, interleukin-6, and interferon (ifn)beta, from lps-activated microglial cells. |
2010-02-08 |
2023-08-12 |
mouse |
| Alexander F Hoffman, Nora Laaris, Masahito Kawamura, Susan A Masino, Carl R Lupic. Control of cannabinoid CB1 receptor function on glutamate axon terminals by endogenous adenosine acting at A1 receptors. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 30. issue 2. 2010-02-01. PMID:20071517. |
marijuana is a widely used drug that impairs memory through interaction between its psychoactive constituent, delta-9-tetrahydrocannabinol (delta(9)-thc), and cb(1) receptors (cb1rs) in the hippocampus. |
2010-02-01 |
2023-08-12 |
mouse |
| Elizabeth J Rahn, Andrea G Hohman. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 6. issue 4. 2010-01-25. PMID:19789075. |
cannabinoids, drugs that share the same target as delta(9)-tetrahydrocannabinol (delta(9)-thc), the psychoactive ingredient in cannabis, have the potential to address this unmet need. |
2010-01-25 |
2023-08-12 |
human |
| Elizabeth J Rahn, Andrea G Hohman. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 6. issue 4. 2010-01-25. PMID:19789075. |
in humans, effects of smoked marijuana, synthetic delta(9)-thc analogs (e.g., marinol, cesamet) and medicinal cannabis preparations containing both delta(9)-thc and cannabidiol (e.g., sativex, cannador) in neuropathic pain states are reviewed. |
2010-01-25 |
2023-08-12 |
human |